Compound dossier · evidence, sources, and live market
PT-141
Melanocortin peptide Moderate evidence 3 cited studies 80 live vendors
PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist derived from the peptide Melanotan II, studied in laboratory and preclinical models for its activity at melanocortin receptors such as MC3R and MC4R. It is supplied as a research-use-only material and is not intended for human or veterinary use. This index tracks per-milligram pricing for PT-141 across research-chemical (RUO) vendors so researchers can compare current listings.
Evidence brief
PT-141 (bremelanotide) is a melanocortin-receptor agonist approved by the US FDA and studied in two phase 3 randomized controlled trials for hypoactive sexual desire disorder in premenopausal women.
first-party prices captured 37m ago
Compare by exact vialThe small sealed glass container a compound ships in. size: 5mg (4 vendors)10mg (74 vendors)
FDA-approved as bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women; not approved in the EU or UK.Research use only — not medical advice.
These figures are what pepmg still publishes about price: the floor, the middle, the spread and how many sources we track, computed from listings we captured first-party and refreshed on the same schedule as always. We no longer publish the individual listings or the sellers behind them.
Computed from 84 in-stock listings across 80 sources we captured first-party, with bulk vials, blends and statistical outliers excluded so the figures compare like with like. The spread is the highest tracked price divided by the lowest — how much the same milligram varies depending on where you look. The chart is the daily minimum; days we did not capture are left out rather than filled in.
- What the research says about PT-141 (bremelanotide) Moderate evidence
PT-141 (bremelanotide) is a melanocortin-receptor agonist approved by the US FDA and studied in two phase 3 randomized controlled trials for hypoactive sexual desire disorder in premenopausal women.
Read the full review →
- Bremelanotide: First Approval PubMed ↗
Bremelanotide (Vyleesi™) is a melanocortin receptor agonist recently approved in the USA for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire…
- Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder PubMed ↗
Objective: To review data regarding bremelanotide, a recently approved therapy for hypoactive sexual desire disorder (HSDD). Data Sources: Literature search of Medline, SCOPUS, and EMBASE was performed using the search terms bremelanotide,…
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire PubMed ↗
Hypoactive sexual desire disorder (HSDD) is a persistent deficiency or absence of sexual fantasies and desire resulting in significant distress or interpersonal difficulty. Women with this disorder may display a lack of motivation for…
A few representative studies, each summarized on this site with the PubMed record linked beside it — not an endorsement or a claim that any result applies to human use. Read them and judge for yourself. Everything here is research use only.
▸ Why compare $/mg for PT-141?
Per-mg prices vary because vendors sell PT-141 in different vial sizes, synthesis batches, and stated purity grades, and because packaging, lyophilization, and shipping overhead get distributed differently across small versus bulk quantities. Comparing normalized $/mg alongside a current COA lets a researcher weigh cost against documented identity and purity rather than headline vial price alone.
▸ Reading the COA
For PT-141, confirm identity by mass spectrometry against the expected monoisotopic mass (roughly 1024–1025 Da for the free peptide, molecular formula C50H68N14O10) and verify HPLC purity is reported, with many research buyers treating >=98% as a reasonable threshold. Check that the COA is lot-matched to the vial you receive and dated. Common flags on a melanocortin peptide like this include truncated or deletion sequences and acetate/TFA counter-ion content, so scan for reported related-substance peaks and residual-solvent notes rather than accepting a purity number in isolation.
▸ FAQ
▸ Same cluster
| Selank | $2.32/mg | |
| Semax | $0.84/mg | |
| DSIP | $2.96/mg | |
| Kisspeptin | $2.50/mg | |
| Thymosin Alpha-1 | $3.90/mg | |
| IGF-1 LR3 | $23.99/mg | |
| LL-37 | $4.60/mg | |
| VIP | $3.79/mg | |
| Thymalin | $3.45/mg | |
| Thymulin | $4.00/mg | |
| MGF | $10.00/mg | |
| Follistatin | $44.91/mg | |
| PNC-27 | $4.83/mg | |
| Gonadorelin | $6.18/mg | |
| Teriparatide | — | |
| HCG | —/mg | |
| Oxytocin | $3.96/mg | |
| Dihexa | $6.50/mg | |
| Adamax | $4.29/mg | |
| Cerebrolysin | $0.69/mg | |
| P-21 | $7.50/mg | |
| Methylene Blue | $1.60/mg | |
| Pinealon | $2.45/mg | |
| Cartalax | $2.21/mg | |
| Cardiogen | $2.29/mg | |
| Testagen | $1.80/mg | |
| Vilon | $2.15/mg | |
| Livagen | $2.70/mg | |
| Vesugen | $2.45/mg | |
| Prostamax | $2.48/mg | |
| Ovagen | $2.45/mg | |
| Cortagen | $2.35/mg | |
| Thymogen | $2.45/mg | |
| Chonluten | $2.45/mg | |
| Bronchogen | $2.50/mg | |
| Pancragen | $2.56/mg |